Miriam Ezenwaka
Psychiatric/Mental Health · Washington, DCNPI 1356061717
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 240 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,180, more than ten times the $71 reported in 2023. Among psychiatric/mental health clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 240 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$647
- E.r. Squibb & Sons, L.L.C.$643
- Alkermes, Inc.$602
- Johnson & Johnson$506
- Otsuka America Pharmaceutical, Inc.$484
- plus $2K from 5 others
What the payments were for
- Food & beverage$5,47299%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 49 | $1,057 |
| Teva Pharmaceuticals USA, Inc. | 28 | $647 |
| E.r. Squibb & Sons, L.L.C. | 28 | $643 |
| Alkermes, Inc. | 33 | $602 |
| Johnson & Johnson | 14 | $506 |
| Otsuka America Pharmaceutical, Inc. | 23 | $484 |
| AbbVie | 20 | $428 |
| Vanda Pharmaceuticals Inc. | 13 | $414 |
| Lundbeck LLC | 19 | $383 |
| Neurocrine Biosciences, Inc. | 12 | $364 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$125
How this compares
$5,551 in reported general payments places this provider in the 95th percentile of 137 psychiatric/mental health providers in District of Columbia.
See all psychiatric/mental health providers in District of Columbia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 85 | $220,777 |
| Abilify MaintenaAripiprazole | 46 | $118,808 |
| Risperidone ErRisperidone Microspheres | 19 | $30,434 |
| Risperdal ConstaRisperidone Microspheres | 14 | $29,161 |
| AristadaAripiprazole Lauroxil | 17 | $26,656 |
| Haloperidol Decanoate | 158 | $5,152 |
| Fluphenazine Decanoate | 41 | $3,170 |
| Fluphenazine Hcl | 22 | $2,704 |
| Aripiprazole | 33 | $1,857 |
| Benztropine Mesylate | 183 | $1,525 |
| Haloperidol | 63 | $1,331 |
| Divalproex Sodium | 114 | $1,178 |
| Haloperidol Decanoate 100Haloperidol Decanoate | 30 | $1,111 |
| Olanzapine | 94 | $1,104 |
| Perphenazine | 16 | $857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $506 | $249,93999 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $484 | $118,80846 claims |
| Alkermes, Inc.Aristada | $602 | $26,65617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 137 psychiatric/mental health providers in District of Columbia.
Other psychiatric/mental health in Washington
- Erin WalczykowskiWashington$349K
- Caroline BonuWashington$16K
- Orin GreeneWashington$4K
- Hope AchoronyeWashington$4K
- Samantha HyltonWashington$4K
- Nkechi OnwucheWashington$4K
- Emmanuel Kamdem SangoWashington$4K
- Arithia HardenWashington$4K
- Zion DestaWashington$4K
- Collette OdiboWashington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.